Nicholas Investment Partners LP Sells 33,632 Shares of Sage Therapeutics, Inc. (SAGE)

Nicholas Investment Partners LP lessened its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 44.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 42,173 shares of the biopharmaceutical company’s stock after selling 33,632 shares during the quarter. Nicholas Investment Partners LP owned about 0.11% of Sage Therapeutics worth $2,627,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SAGE. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Sage Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 138 shares during the last quarter. Keybank National Association OH increased its stake in Sage Therapeutics by 10.6% during the second quarter. Keybank National Association OH now owns 3,798 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Sage Therapeutics by 19.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 497 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Sage Therapeutics by 0.9% during the second quarter. Ameriprise Financial Inc. now owns 59,336 shares of the biopharmaceutical company’s stock worth $4,723,000 after acquiring an additional 552 shares during the last quarter. Finally, Amalgamated Bank increased its stake in Sage Therapeutics by 18.6% during the second quarter. Amalgamated Bank now owns 4,378 shares of the biopharmaceutical company’s stock worth $349,000 after acquiring an additional 686 shares during the last quarter. 95.40% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently weighed in on SAGE. Royal Bank Of Canada dropped their price objective on Sage Therapeutics from $145.00 to $137.00 and set an “outperform” rating for the company in a research note on Monday, November 27th. Stifel Nicolaus began coverage on Sage Therapeutics in a research note on Wednesday, August 9th. They issued a “buy” rating and a $104.00 price objective for the company. BidaskClub cut Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $112.00 price objective (up from $85.67) on shares of Sage Therapeutics in a research note on Friday, November 17th. Finally, Chardan Capital reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, September 13th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $105.14.

Sage Therapeutics, Inc. (NASDAQ SAGE) opened at $89.79 on Wednesday. Sage Therapeutics, Inc. has a fifty-two week low of $44.55 and a fifty-two week high of $100.50.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue was up .0% compared to the same quarter last year. equities research analysts expect that Sage Therapeutics, Inc. will post -7.4 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/06/nicholas-investment-partners-lp-sells-33632-shares-of-sage-therapeutics-inc-sage.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

What are top analysts saying about Sage Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sage Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit